GlobalFoundries is today's stock review because it is moving against the market on a substantial company announcement. The question is what the new fabs could earn for shareholders, and how long it will take to get there.
At 2:00 p.m. ET on October 14, GFS was observed at $48.37, up 3.58% from its previous regular-session close of $46.70. SPY was down 1.38% and QQQ 2.14% at nearly simultaneous observations. Those are dated intraday observations, not final closes.
What the $21 billion actually funds
GlobalFoundries says Japan will provide up to $21 billion for two new fabs at its Malta, New York site, with GF supplying technology and operating the facilities. The initial roughly $10 billion fab is expected online in 2029; a second roughly $10 billion facility is conditional. This is project investment, not $21 billion of immediate GF revenue, earnings or cash.
There are two separate arrangements: $955 million of existing CHIPS funding is being reallocated, and Commerce will receive approximately 4% GF equity. Those terms matter when judging the shareholder benefit. Today's announcement does not quantify the project's eventual profit contribution or fully explain the equity mechanics. Company announcement.
The investment case depends on demand, utilization, operating terms and returns from the capacity. A large funding number alone cannot settle those questions. The 2029 schedule also makes this a different catalyst from an immediate earnings increase.
A recovery attempt below the long-term average
The snapshot sat above the 50-session SMA of $47.83, but below the 200-session SMA of $54.67, both calculated from completed regular sessions through October 13. Intraday strength above an average is useful; it still needs a daily close to confirm where the session finishes.
The first nearby reference is the October 13 intraday high at $48.44. A reclaim and hold above it would put the observed October 14 high of $49.80 back in focus. Beyond that, the October 8 high at $51.45 sits just below an older unfilled daily range gap at $51.61–$53.27 from August 18. These are chart references, not guaranteed targets.
If the recovery loses the 50-day average, watch the observed $47.28 intraday low, then the previous close at $46.70 and October 13 low at $46.22. A lower unfilled daily gap sits at $44.16–$44.56, from September 17. For a daily retest setup, we want price to test the relevant level and close above it, rather than counting a brief intraday bounce as confirmation.
Today's observed trading range overlaps the prior day's range. The morning jump therefore should not be described as a new, fully open daily range gap. Older gaps are calculated from adjacent completed daily highs and lows and tracked for subsequent fills. Price history.
The wider chart matters. A $89.96 closing peak on May 26 declined to $42.75 on September 15, before the rebound reached a $50.17 close on October 2. That older decline and later rebound are separate moves. The new fab announcement arrives while the stock is still working through a much larger recovery; one positive session does not erase that history.
Revenue growth has not improved every profit measure
For Q2 ended June 30, GF reported $1.786 billion of revenue, compared with $1.688 billion a year earlier. IFRS gross margin improved to 28.3%, but operating profit fell to $174 million from $196 million, and net income to $167 million from $228 million. Non-IFRS operating margin was 16.7%, compared with 9.7% under IFRS. The adjustments and reported results answer different questions.
Operating cash flow of $405 million, less $411 million of property, equipment and intangible purchases, plus $3 million of government grants, produced negative $3 million of company-defined adjusted free cash flow. Revenue growth and funding headlines therefore should not be confused with strong current free cash generation. Q2 results and reconciliations.
Balance-sheet room, with a valuation to consider
At June 30, cash and marketable securities totaled $3.303 billion, versus $1.122 billion of debt, with leases reported separately. That is a dated balance-sheet comparison, not today's available cash. The new announcement does not establish an updated balance sheet.
There is also a price to pay for the recovery. Summing the last four reported quarters gives $1.28 of IFRS diluted EPS and $1.82 of non-IFRS diluted EPS. At the $48.37 snapshot, those imply approximately 37.79 times and 26.58 times earnings, respectively. These are simple trailing-quarter calculations, not a forward consensus multiple or a valuation of the new fabs. Q3 2025, Q4 2025, Q1 2026, Q2 2026.
The small insider purchase was dividend reinvestment
Our Insider Analyzer adds useful context for transactions dated July 14–October 14: 17 eligible ordinary-share sale rows totaling approximately $937,000, all referencing trading plans. The single P-coded purchase was only $767.40, and its filing identifies it as automatic dividend reinvestment. It should not be presented as a discretionary insider buying signal. Hogan filing and DRIP footnote.
The chart aggregates same-date transactions and places markers at the stock's daily close, not the insider execution price. These included filings describe reported ownership changes; plan-linked sales do not establish a new bearish decision or explain today's move. Grants, withholding and other transaction codes are separate from the purchase/sale totals.
What would strengthen the case?
The business case improves with clearer project economics, demand commitments, profitable utilization and cash generation that survives the investment cycle. The chart improves separately if the recovery holds the intermediate average on daily closes and works through the overhead references.
The case weakens if timing slips, returns disappoint or the shareholder terms absorb more of the benefit than expected. The next quarterly results will help test the existing business; the new fabs will take longer to prove themselves.
Our read: GFS has a meaningful company catalyst and relative strength on a weak market day. The useful next step is to separate the opportunity created by external project funding from the earnings and cash that can ultimately reach shareholders.
Explore the earnings calendar, Daily Levels and other stock reviews.
And remember, this is market research only, not a recommendation to buy or sell. USD unless stated. Price observations are dated October 14 at 2:00 p.m. ET; completed daily candles and averages end October 13. Returns exclude dividends. Operating figures cover Q2 ended June 30; trailing EPS spans Q3 2025 through Q2 2026.